Firategrast for relapsing remitting multiple sclerosis: a phase 2, randomised, double-blind, placebo-controlled trial

Keyphrases

• Randomized Placebo-controlled Trial 100%
• Relapsing-remitting multiple Sclerosis 100%
• Firategrast 100%
• Placebo 33%
• Alpha4 25%
• Gadolinium-enhancing Lesions 25%
• β-integrin 25%
• High Dose 16%
• Cumulative Counts 16%
• Core Follow 16%
• Multiple Sclerosis 8%
• Short-acting 8%
• Treatment Group 8%
• Adverse Events 8%
• Placebo Groups 8%
• Safety Concerns 8%
• Generalized Linear Model 8%
• Urinary Tract Infection 8%
• Randomized Double-blind 8%
• Brain Lesions 8%
• Lesion number 8%
• Treatment Duration 8%
• Placebo-controlled 8%
• Twice a Day 8%
• Progressive multifocal Leukoencephalopathy 8%
• Extended Follow-up 8%
• Gadolinium 8%
• Therapeutic Monoclonal Antibody 8%
• Block Randomization 8%
• Brain Scans 8%
• Treatment Phase 8%
• Negative Binomial Distribution 8%
• JC Virus 8%
• Dose-ranging Study 8%
• Imaging Endpoints 8%

Immunology and Microbiology

• Relapsing Remitting Multiple Sclerosis 100%
• Integrin 100%
• Drug Megadose 66%
• JC Virus 33%
• Monoclonal Antibody Therapy 33%
• Urinary Tract 33%
• Multiple Sclerosis 33%
• Infection 33%